Trial Profile
A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension; Resistant hypertension
- Focus Pharmacodynamics
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 08 Sep 2020 Primary endpoint (Body weight) has been met.
- 08 Sep 2020 Results published in the Clinical Pharmacology and Therapeutics.
- 11 Jan 2017 Status changed from recruiting to completed.